In re: Bioserv Corporation

United States Bankruptcy Appellate Panel for the Ninth Circuit·Decided June 20, 2023·No. 22-1213·Unpublished

Opinion

FILED

NOT FOR PUBLICATION

JUN 20 2023

UNITED STATES BANKRUPTCY APPELLATE PANEL SUSAN M. SPRAUL, CLERK U.S. BKCY. APP. PANEL

OF THE NINTH CIRCUIT OF THE NINTH CIRCUIT

In re: BAP No. SC-22-1213-BGF BIOSERV CORPORATION, Debtor. Bk. No. 14-08651-MM11

GXP CAPITAL, LLC, Adv. No. 21-90063-MM Appellant,

v. MEMORANDUM∗ ARGONAUT MANUFACTURING SERVICES, INC.; TELEGRAPH HILL PARTNERS III, L.P.; TELEGRAPH HILL PARTNERS III, INVESTMENT MANAGEMENT, LLC, Appellees.

Appeal from the United States Bankruptcy Court for the Southern District of California Margaret M. Mann, Bankruptcy Judge, Presiding

Before: BRAND, GAN, and FARIS, Bankruptcy Judges.

INTRODUCTION

Appellant GXP Capital, LLC ("GXP") appeals an order dismissing its adversary complaint for various state-law claims against appellees Argonaut Manufacturing Services, Inc. ("Argonaut"), Telegraph Hill Partners III, L.P. and Telegraph Hill Partners III, Investment Management, LLC ("THP") (together

∗ This disposition is not appropriate for publication. Although it may be cited for whatever persuasive value it may have, see Fed. R. App. P. 32.1, it has no precedential value, see 9th Cir. BAP Rule 8024-1.

with Argonaut, "Defendants"). Defendants moved to dismiss GXP's complaint under Civil Rules 12(b)(1)1 and (6), arguing that GXP lacked Article III standing and failed to state a claim for relief. The bankruptcy court determined that GXP lacked Article III standing and dismissed all claims under Civil Rule 12(b)(1). It also determined that some of the claims were time-barred and alternatively dismissed those claims, without prejudice, under Civil Rule 12(b)(6).

We conclude that the bankruptcy court did not err in determining that GXP failed to establish Article III standing and dismissing all claims under Civil Rule 12(b)(1). Even if GXP had standing, we conclude that GXP failed to state a claim for relief under Civil Rule 12(b)(6) on its claims for breach of contract and misappropriation of trade secrets.2 Accordingly, we AFFIRM.

FACTS

A. Events in the main case Debtor Bioserv Corporation ("Debtor") was in the pharmaceutical business. Albert Hansen was its chairman and CEO. Hansen is also the CEO of KESA Partners, Inc. ("KESA"), which acquired Debtor in November 2012. Between November 2012 and when Debtor filed for bankruptcy in October 2014, it had incurred net losses in excess of $2.5 million. Hansen is now the CEO

1 Unless specified otherwise, all chapter and section references are to the Bankruptcy Code, 11 U.S.C. §§ 101-1532, all "Rule" references are to the Federal Rules of Bankruptcy Procedure, and all "Civil Rule" references are to the Federal Rules of Civil Procedure.

2 GXP did not challenge in its opening brief the bankruptcy court's dismissal of its

remaining five claims under Civil Rule 12(b)(6) as time-barred, so any appeal of the dismissal of those claims on that basis has been waived. Momox-Caselis v. Donohue, 987 F.3d 835, 842 (9th Cir.), cert. denied, 142 S. Ct. 402 (2021) (portion of trial court's adverse ruling not challenged in opening appeal brief is waived).

of the reorganized debtor, GXP CDMO, Inc.; appellant GXP is its subsidiary.

Debtor filed a chapter 11 bankruptcy case on October 31, 2014. Months later, Hansen pursued investors to help reorganize Debtor. One entity he met with was Argonaut. Hansen sent an email presentation about Debtor to Wayne Woodard, CEO of Argonaut. 3 Woodard toured Debtor's facility and was given Debtor's financial information. During this time, Woodard signed on behalf of Argonaut two nondisclosure agreements ("NDAs"). Hansen also shared with Woodard his personal views of the Official Committee of Unsecured Creditors ("OCC") and its counsel and Debtor's plans for reorganization. Ultimately, negotiations between Debtor and Argonaut ceased on October 30, 2015. No one outside of the parties was aware of these negotiations during this time period.

Meanwhile, Debtor filed a disclosure statement and proposed plan of reorganization ("First Plan"). The First Plan proposed a distribution to general unsecured creditors of preferred stock in Debtor, which Debtor estimated would provide a 15% to 50% return.

Several key events occurred in Debtor's case in late 2015. In October, Debtor moved for approval of its disclosure statement. In addition to its other debts, Debtor reported in its October 2015 operating report that it owed $494,000 in unpaid taxes.

Debtor also sought to reject its executory contracts with Tenax Therapeutics, Inc. ("Tenax"). Debtor described the soured relationship between the parties and current dispute over an outstanding debt allegedly owed by

3 THP was to provide Argonaut the funds for any potential investment in Debtor.

Tenax. Tenax opposed the rejection motion and asserted that Debtor was holding some of Tenax's equipment "hostage" in an attempt to coerce a payment for a debt Tenax claimed it did not owe to Debtor.

On November 10, the OCC filed its statement of position on the disclosure statement and First Plan. The OCC did not object to the disclosure statement, but it did express concerns with the First Plan: whether KESA's contributions would suffice to keep Debtor afloat; whether there was enough new business to sustain Debtor's future success; and whether Debtor was able to pay its administrative expense obligations.

In addition, Tenax filed an objection to Debtor's disclosure statement. It argued that the disclosure statement failed to provide sufficient details about litigation claims Debtor wished to pursue and how Debtor planned to repay KESA for unapproved, postpetition advances of over $200,000. Tenax also argued that the First Plan was not confirmable; it violated the absolute priority rule and was not feasible.

On November 17, THP sent the OCC a nonbinding offer (the "Offer") to acquire Debtor's assets for $1.27 million. That same day, Tenax filed an emergency motion to appoint a chapter 11 trustee to administer Debtor's case ("Appointment Motion"). Tenax asserted that a trustee should be appointed due to Debtor's "incompetence and gross mismanagement" and the "inherent conflict" and "self-dealing" of KESA and Hansen. Tenax again noted the equipment dispute with Debtor and asserted that Debtor was intentionally breaching another agreement between the parties by refusing to ship pharmaceuticals to one of Tenax's customers. Tenax also complained of Debtor's

litigious nature and accused Debtor of abusing the bankruptcy process by using it as a litigation platform to "shake down" creditors and customers and maximize profit to KESA.

On November 18, the OCC filed a statement supporting the Appointment Motion. The OCC disclosed that it had received the Offer to purchase Debtor's assets, but it would not disclose the buyer's identity per the buyer's instruction. Though it had just received the Offer the previous day, the OCC maintained that it would provide cash for unsecured creditors and was superior to Debtor's stock offer. The OCC asserted that a trustee must be appointed to evaluate the Offer because Debtor could not be trusted to consider and respond to it in good faith.

Debtor opposed the Appointment Motion. It denied Tenax's allegations of misconduct and argued that Tenax had not submitted any evidence supporting cause to appoint a trustee.

The bankruptcy court issued a tentative ruling on the Appointment Motion, stating that it was inclined to appoint a trustee given the OCC's support. Debtor filed a response to the tentative. The bankruptcy court also issued a tentative ruling rejecting the First Plan, finding that it violated the absolute priority rule and was infeasible.

On November 19, the bankruptcy court held a hearing on the Appointment Motion and Debtor's disclosure statement. Counsel for Tenax informed the court that the dispute with Debtor had been resolved. The court continued the Appointment Motion to December 17 to give Debtor "full due process" before deciding whether to appoint a trustee.

Free access — add to your briefcase to read the full text and ask questions with AI

In re: Bioserv Corporation, (bap9 2023).

In re: Bioserv Corporation (In re: Bioserv Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Chandler v. State Farm Mutual Automobile Insurance
598 F.3d 1115 (Ninth Circuit, 2010)
Neitzke v. Williams
490 U.S. 319 (Supreme Court, 1989)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Retz v. Samson (In Re Retz)
606 F.3d 1189 (Ninth Circuit, 2010)
Daniels-Hall v. National Education Ass'n
629 F.3d 992 (Ninth Circuit, 2010)
Reese v. BP Exploration (Alaska) Inc.
643 F.3d 681 (Ninth Circuit, 2011)
Conservation Force v. Salazar
646 F.3d 1240 (Ninth Circuit, 2011)
Harry Franklin v. Ms. Murphy and Hoyt Cupp
745 F.2d 1221 (Ninth Circuit, 1984)
White v. Lee
227 F.3d 1214 (Ninth Circuit, 2000)
United States v. Lummi Indian Tribe
235 F.3d 443 (Ninth Circuit, 2000)
United States v. Hinkson
585 F.3d 1247 (Ninth Circuit, 2009)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Boschetto v. Hansing
539 F.3d 1011 (Ninth Circuit, 2008)
Vu v. California Commerce Club, Inc.
58 Cal. App. 4th 229 (California Court of Appeal, 1997)
Fresno Motors, LLC v. Mercedes-Benz USA, LLC
771 F.3d 1119 (Ninth Circuit, 2014)
Mele v. Mele (In Re Mele)
501 B.R. 357 (Ninth Circuit, 2013)
Spokeo, Inc. v. Robins
578 U.S. 330 (Supreme Court, 2016)